Which company produces and develops Acalatinib/Acalatinib?

Acalabrutinib (Acalabrutinib) is a new generation of BTK inhibitor, and its research and development and production background have always been a topic of close concern among the medical community and patient groups. The drug was originally developed by the biopharmaceutical company Acerta Pharma, a biopharmaceutical company based in the United States. As drug research and development entered the late stages and clinical value continued to become more prominent, the global multinational pharmaceutical company AstraZeneca acquired a majority stake in the company through mergers and acquisitions in 2016, thus bringing acotinib into the international commercial promotion stage. Today, this drug is approved for marketing under different trade names in many countries and regions, and has become one of the important choices for the treatment of hematological tumors, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).

As the main manufacturer and promoter of acotinib, AstraZeneca’s global pharmaceutical factories and R&D centers ensure the supply and clinical application of the drug. The company has production and R&D bases in the UK, the United States and many European countries, allowing acotinib to be produced under conditions that comply with international GMP standards to ensure drug quality and stability. It is worth mentioning that acotinib is not only widely used in the European and American markets, but has also been approved in some Asian countries, becoming an important member of the BTK inhibitor family after ibrutinib.

From a research and development perspective, the emergence of acotinib is not just a simple substitution, but an optimization of the molecular structure and mechanism of action. By more selectively inhibiting BTK (Bruton's tyrosine kinase), it reduces interference with other kinases, resulting in relatively few clinical side effects and better tolerability for patients. It is this research and development concept that has gradually occupied an important position in international clinical guidelines.

Reference materials:https://www.calquence.com/